| Postmenopausal osteoporosis (PO) is a systemic bone disease caused by estrogen deficiency and aging, which is characterized by low bone mineral density (BMD) and microstructural deterioration of the bone tissue, leading to the increase of osteoporotic fracture risk. In the development of PO, the underlying pathogenesis is complex and multi-faceted. Estrogen deficiency is an important cause of increased bone resorption and accelerated bone loss. At the same time, the lack of estrogen and the aging of the body lead to an increase in oxidative stress (OS) levels, which is one of the main mechanisms of PO. Treatment of elderly postmenopausal osteoporosis is currently more effective with estrogen replacement therapy, but it also increases the risk of breast cancer, uterine cancer, and cardiovascular events. Therefore, the search for effective anti-oxidative stress drugs to treat PO has attracted the attention of more and more researchers. The natural plant compound represented by resveratrol (RES) is a natural antioxidant with anti-oxidation and anti-aging effects. It can effectively treat PO through a variety of pathways to inhibit oxidative stress in the body, promote osteogenic differentiation and reduce bone loss, and regulate bone turnover. In this paper, the anti-oxidation mechanism of resveratrol in PO and its research progress are reviewed. |